Home Gemelli Biotech

Gemelli Biotech

Second-Generation Blood Test for Irritable Bowel Syndrome Validated as Providing Most Conclusive Diagnosis of Inclusion for IBS

Available commercially as is-smart™, the test could provide physicians with the most conclusive data currently attainable for ruling in IBS. Primarily applicable to patients with a diarrheal component to their symptoms, the test could serve up to two-thirds of the 45 million Americans suffering from IBS.